drugset / Trial / NCT00318656

24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes

NCT00318656

Phase 4 Completed 23 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

A better glycemic control is associated with less complications (cardiac diseases, blindness, etcetera) for type 2 diabetic patients. The objective is to study if rosiglitazone may lead to a more regular glycemic pattern with less hyperglycemia and hypoglycemia episodes than with a sulphonylurea (glimepiride).

Timeline

Start
2005-11
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Glimepiride Small molecule
Subject Rosiglitazone Small molecule
Background Metformin Small molecule